Abstract:Multiple sclerosis [MS] is a progressive autoimmune condition that primarily affects young people and is characterized by demyelination and neurodegeneration of the central nervous system [CNS]. This in-depth review explores the complex involvement of oligodendrocytes, the primary myelin- producing cells in the CNS, in the pathophysiology of MS. It discusses the biochemical processes and signalling pathways required for oligodendrocytes to function and remain alive, as well as how they might fail and cause demyelination to occur. We investigate developing therapeutic options that target remyelination, a fundamental component of MS treatment. Remyelination approaches promote the survival and differentiation of oligodendrocyte precursor cells [OPCs], restoring myelin sheaths. This improves nerve fibre function and may prevent MS from worsening. We examine crucial parameters influencing remyelination success, such as OPC density, ageing, and signalling pathway regulation [e.g., Retinoid X receptor, LINGO-1, Notch]. The review also examines existing neuroprotective and antiinflammatory medications being studied to see if they can assist oligodendrocytes in surviving and reducing the severity of MS symptoms. The review focuses on medicines that target the myelin metabolism in oligodendrocytes. Altering oligodendrocyte metabolism has been linked to reversing demyelination and improving MS patient outcomes through various mechanisms. We also explore potential breakthroughs, including innovative antisense technologies, deep brain stimulation, and the impact of gut health and exercise on MS development. The article discusses the possibility of personalized medicine in MS therapy, emphasizing the importance of specific medicines based on individual molecular profiles. The study emphasizes the need for reliable biomarkers and improved imaging tools for monitoring disease progression and therapy response. Finally, this review focuses on the importance of oligodendrocytes in MS and the potential for remyelination therapy. It also underlines the importance of continued research to develop more effective treatment regimens, taking into account the complexities of MS pathology and the different factors that influence disease progression and treatment.

The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells

Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management

Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells

[Mechanisms Underlying Remyelination with Special Focus on Demyelination Models of Multiple Sclerosis].

Anti‐ and pro‐inflammatory milieu differentially regulate differentiation and immune functions of oligodendrocyte progenitor cells

Remyelinating Pharmacotherapies in Multiple Sclerosis

M2 Microglia and Macrophages Drive Oligodendrocyte Differentiation During CNS Remyelination

Remyelination in the CNS: from biology to therapy

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

Glial Cells as Key Regulators in Neuroinflammatory Mechanisms Associated with Multiple Sclerosis

The neuropathobiology of multiple sclerosis

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Cell‐based experimental strategies for myelin repair in multiple sclerosis

Immune System Dysregulation in the Progression of Multiple Sclerosis: Molecular Insights and Therapeutic Implications

New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

Preventing production of new oligodendrocytes impairs remyelination and sustains behavioural deficits after demyelination

Beyond Myelination: Possible Roles of the Immune Proteasome in Oligodendroglial Homeostasis and Dysfunction

Circulating platelets modulate oligodendrocyte progenitor cell differentiation during remyelination